EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

“Time Is Brain” – for Cell Therapies

Hao Yin iD, Dominikus Brian iD, Rebecca Z Weber iD, Patrick D Lyden iD, Ruslan Rust iD

Advanced Science · 2026-01 · 13 (6)

DOI: 10.1002/advs.202519579 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 18.11.2025. Verfasst von Hao Yin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Ontario, N6A 5C1, Canada. Hauptthemen laut MEDLINE: Stroke, Cell- and Tissue-Based Therapy, Brain, Stem Cell Transplantation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The principle “time is brain” has long guided acute stroke treatment, emphasizing that earlier intervention improves outcomes. While this dictum applies to current gold‐standard reperfusion therapies, its relevance to emerging regenerative approaches such as stem cell therapy remains to be established. A growing body of preclinical and clinical studies suggests that timing of cell delivery is a key determinant of graft survival, integration and therapeutic efficacy, largely through interactions with the evolving post‐stroke microenvironment. Here, we discuss how early transplantation may access salvageable tissue but faces a hostile inflammatory microenvironment, whereas transplantation at the subacute or chronic phase benefits from a more permissive milieu but by then much of the tissue has been irreversibly lost. We further suggest the optimal window also depends on cell type and mechanism of action: neuroprotective or immunomodulatory grafts may benefit from earlier delivery, while cells requiring long‐term survival and integration may perform better later. Thus, “time is brain” also applies to cell therapies, but it may require aligning graft delivery with the evolving post‐stroke microenvironment rather than the acute therapeutic window. Identifying biomarkers that track inflammatory changes, vascular remodeling and brain damage could personalize this “window of receptivity” and guide tailored future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StrokeCell- and Tissue-Based TherapyBrainStem Cell TransplantationHumansAnimals

Stichwörter der Autor:innen

cell therapycell transplantationneural stem cellsstroke

Autor:innen und Institutionen

  • Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Ontario, N6A 5C1, Canada.
  • OrganoBit BioIntelligence Pte Ltd, Singapore, 049422, Singapore.
  • Department of Physiology and Neuroscience, University of Southern California, Los Angeles, CA, 90033, USA.
  • Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA.

ORCID-Profile: Hao Yin, Dominikus Brian, Rebecca Z Weber, Patrick D Lyden, Ruslan Rust

Zitieren

APA

Yin, H., Brian, D., Weber, R. Z., Lyden, P. D., & Rust, R. (2026). “Time Is Brain” – for Cell Therapies. Advanced Science, 13(6). https://doi.org/10.1002/advs.202519579

Vancouver

Yin H, Brian D, Weber RZ, Lyden PD, Rust R. “Time Is Brain” – for Cell Therapies. Advanced Science. 2026;13(6). doi:10.1002/advs.202519579

BibTeX
@article{Yin2026,
  author = {Yin, Hao and Brian, Dominikus and Weber, Rebecca Z and Lyden, Patrick D and Rust, Ruslan},
  title = {“Time Is Brain” – for Cell Therapies},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {6},
  doi = {10.1002/advs.202519579}
}
Kostenlos starten →